Evaluation of 5-HT2A and mGlu2/3 receptors in postmortem prefrontal cortex of subjects with major depressive disorder: Effect of antidepressant treatment

Neuropharmacology

Volumn 86, Issue , 2014, Pages 311-318

  Muguruza, Carolina ^a   Miranda Azpiazu, Patricia ^a   Díez Alarcia, Rebeca ^a   Morentin, Benito ^b   González Maeso, Javier ^c   Callado, Luis F ^a,d   Meana, J Javier ^a,d  

^a UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

^b Basque Institute of Legal Medicine   (Spain)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^d BIOCRUCES BIZKAIA HEALTH RESEARCH INSTITUTE   (Spain)

Author keywords

5 HT2A receptors; Antidepressants; Depression; Human brain; mGlu2 3 receptors

Indexed keywords

2 AMINO 2 (2 CARBOXYCYCLOPROPYL) 3 (XANTHEN 9 YL)PROPIONIC ACID; ANTIDEPRESSANT AGENT; CITALOPRAM; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; KETANSERIN; MESSENGER RNA; METABOTROPIC RECEPTOR 2; METABOTROPIC RECEPTOR 3; MIRTAZAPINE; REBOXETINE; SEROTONIN 2A RECEPTOR; AMINO ACID; METABOTROPIC RECEPTOR; MIANSERIN; MORPHOLINE DERIVATIVE; TRITIUM; XANTHENE DERIVATIVE;

ACTB GENE; ANIMAL TISSUE; ARTICLE; AUTOPSY; CONTROLLED STUDY; DENSITY GRADIENT; DOWN REGULATION; DRUG EFFECT; DRUG MECHANISM; FEMALE; GAPDH GENE; GENE; GENE EXPRESSION; GRM2 GENE; GRM3 GENE; HTR2A GENE; HUMAN; HUMAN TISSUE; MAJOR DEPRESSION; MALE; NONHUMAN; PREFRONTAL CORTEX; RAT; ANALOGS AND DERIVATIVES; ANIMAL; DEPRESSIVE DISORDER, MAJOR; DRUG EFFECTS; METABOLISM; MIDDLE AGED; RADIOASSAY; SPRAGUE DAWLEY RAT;

AMINO ACIDS; ANIMALS; ANTIDEPRESSIVE AGENTS; CITALOPRAM; DEPRESSIVE DISORDER, MAJOR; DOWN-REGULATION; FEMALE; HUMANS; KETANSERIN; MALE; MIANSERIN; MIDDLE AGED; MORPHOLINES; PREFRONTAL CORTEX; RADIOLIGAND ASSAY; RATS, SPRAGUE-DAWLEY; RECEPTOR, SEROTONIN, 5-HT2A; RECEPTORS, METABOTROPIC GLUTAMATE; RNA, MESSENGER; TRITIUM; XANTHENES;

EID: 84907690165     PISSN: 00283908     EISSN: 18737064     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2014.08.009     Document Type: Article

References (59)

1. Y. Ago, K. Yano, R. Araki, N. Hiramatsu, Y. Kita, T. Kawasaki, H. Onoe, S. Chaki, A. Nakazato, H. Hashimoto, A. Baba, K. Takuma, and T. Matsuda Metabotropic glutamate 2/3 receptor antagonists improve behavioral and prefrontal dopaminergic alterations in the chronic corticosterone-induced depression model in mice Neuropharmacology 65 2013 29 38
2. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders: DSM-IV 1994 In: Washington, DC
3. 2 and β-adrenergic receptor binding sites in the brain of suicide victims Arch. Gen. Psychiatry 47 1990 1038 1047
4. F. Artigas Serotonin receptors involved in antidepressant effects Pharmacol. Ther. 137 2013 119 131
5. 18F]-setoperone during depressive illness and antidepressant treatment with clomipramine Biol. Psychiatry 45 1999 180 186
6. 2 receptors in suicide victims Biol. Psychiatry 35 1994 457 463
7. 2A serotonin receptor in the modulation of emotion-based actions? Mol. Neurobiol. 48 2013 841 853
8. 11C]MDL 100,907 Am. J. Psychiatry 163 2006 1580 1587
9. F. Biver, D. Wikler, F. Lotstra, P. Damhaut, S. Goldman, and J. Mendlewicz Serotonin 5-HT2 receptor imaging in major depression: focal changes in orbito-insular cortex Br. J. Psychiatry 171 1997 444 448
10. M.M. Bradford A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding Anal. Biochem. 72 1976 248 254
11. S. Chaki, Y. Ago, A. Palucha-Paniewiera, F. Matrisciano, and A. Pilc mGlu2/3 and mGlu5 receptors: potential targets for novel antidepressants Neuropharmacology 66 2013 40 52
12. S.C. Cheetham, M.R. Crompton, C.L. Katona, and R.W. Horton Brain 5-HT2 receptor binding sites in depressed suicide victims Brain Res. 443 1988 272 280
13. T.J. Crow, A.J. Cross, S.J. Cooper, J.F. Deakin, I.N. Ferrier, J.A. Johnson, M.H. Joseph, F. Owen, M. Poulter, and R. Lofthouse Neurotransmitter receptors and monoamine metabolites in the brains of patients with Alzheimer-type dementia and depression, and suicides Neuropharmacology 23 1984 1561 1569
14. A.M. Feyissa, W.L. Woolverton, J.J. Miguel-Hidalgo, Z. Wang, P.B. Kyle, G. Hasler, C.A. Stockmeier, A.H. Iyo, and B. Karolewicz Elevated level of metabotropic glutamate receptor 2/3 in the prefrontal cortex in major depression Prog. Neuropsychopharmacol. Biol. Psychiatry 34 2010 279 283
15. P.B. Fitzgerald, T.J. Oxley, A.R. Laird, J. Kulkarni, G.F. Egan, and Z.J. Daskalakis An analysis of functional neuroimaging studies of dorsolateral prefrontal cortical activity in depression Psychiatry Res. 148 2006 33 45
16. M. Fribourg, J.L. Moreno, T. Holloway, D. Provasi, L. Baki, R. Mahajan, G. Park, S.K. Adney, C. Hatcher, J.M. Eltit, J.D. Ruta, L. Albizu, Z. Li, A. Umali, J. Shim, A. Fabiato, A.D. MacKerell Jr., V. Brezina, S.C. Sealfon, M. Filizola, J. González-Maeso, and D.E. Logothetis Decoding the signaling of a GPCR heteromeric complex reveals a unifying mechanism of action of antipsychotic drugs Cell 147 2011 1011 1023
17. J.A. Garcia-Sevilla, M. Alvaro-Bartolome, R. Diez-Alarcia, A. Ramos-Miguel, D. Puigdemont, V. Perez, E. Alvarez, and J.J. Meana Reduced platelet G protein-coupled receptor kinase 2 in major depressive disorder: antidepressant treatment-induced upregulation of GRK2 protein discriminates between responder and non-responder patients Eur. Neuropsychopharmacol. 20 2010 721 730
18. J. González-Maeso, R. Ang, T. Yuen, P. Chan, N.V. Weisstaub, J. López-Giménez, M. Zhou, Y. Okawa, L.F. Callado, G. Milligan, J.A. Gingrich, M. Filizola, J.J. Meana, and S.C. Sealfon Identification of a novel serotonin/glutamate receptor complex implicated in psychosis Nature 452 2008 93 97
19. G.G. Gould, M.C. Pardon, D.A. Morilak, and A. Frazer Regulatory effects of reboxetine treatment alone, or following paroxetine treatment, on brain noradrenergic and serotonergic systems Neuropsychopharmacology 28 2003 1633 1641
20. 2A receptors by agonists and antagonists Brain Res. Bul. 56 2001 441 451
21. K. Hawton, and K. van Heeringen Suicide Lancet 373 2009 1372 1381
22. W. Jia, R. Zhang, B. Wu, D. Zun-xiao, Z. Yong-sheng, L. Ping-ping, and F. Zhu Metabotropic glutamate receptor 3 is associated with heroin dependence but not depression or schizophrenia in a Chinese population PLoS One 9 2014 e87247
23. F.C. Kugelberg, G. Apelqvist, B. Carlsson, J. Ahlner, and F. Bengtsson In vivo steady-state pharmacokinetic outcome following clinical and toxic doses of racemic citalopram to rats Br. J. Pharmacol. 132 2001 1683 1690
24. M. Kurita, T. Holloway, A. García-Bea, A. Kozlenkov, A.K. Friedman, J.L. Moreno, M. Heshmati, S.A. Golden, P.J. Kennedy, N. Takahashi, D.M. Dietz, G. Mocci, A.M. Gabilondo, J. Hanks, A. Umali, L.F. Callado, A.L. Gallitano, R.L. Neve, L. Shen, J.D. Buxbaum, M.-H. Han, E.J. Nestler, J.J. Meana, S.J. Russo, and J. González-Maeso HDAC2 regulates atypical antipsychotic responses through the modulation of mGlu2 promoter activity Nat. Neurosci. 15 2012 1245 1254
25. 2A receptor mRNA expression in subjects with major depression, bipolar disorder, and schizophrenia Biol. Psychiatry 55 2004 225 233
26. S. Lowther, F. De Paermentier, M.R. Crompton, C.L. Katona, and R.W. Horton Brain 5-HT2 receptors in suicide victims: violence of death, depression and effects of antidepressant treatment Brain Res. 642 1994 281 289
27. 2 and β-adrenergic receptor binding in the frontal cortices of suicide victims Arch. Gen. Psychiatry 43 1986 954 959
28. 3H]-ketanserin binding sites in different psychiatric disorders Neurochem Int. 42 2003 511 516
29. 2A antagonists and selective serotonin reuptake inhibitors in neuropsychiatric disorders Neuropsychopharmacology 28 2003 402 412
30. F. Matrisciano, I. Panaccione, M. Zusso, P. Giusti, R. Tatarelli, L. Iacovelli, A.A. Mathe, S.H. Gruber, F. Nicoletti, and P. Girardi Group-II metabotropic glutamate receptor ligands as adjunctive drugs in the treatment of depression: a new strategy to shorten the latency of antidepressant medication? Mol. Psychiatry 12 2007 704 706
31. F. Matrisciano, A. Caruso, R. Orlando, M. Marchiafava, V. Bruno, G. Battaglia, S.H. Gruber, D. Melchiorri, R. Tatarelli, P. Girardi, A.A. Mathè, and F. Nicoletti Defective group-II metabotropic glutamate receptors in the hippocampus of spontaneously depressed rats Neuropharmacology 55 2008 525 531
32. C.C. Meltzer, J.C. Price, C.A. Mathis, P.J. Greer, M.N. Cantwell, P.R. Houck, B.H. Mulsant, D. Ben-Eliezer, B. Lopresti, S.T. DeKosky, and C.F. Reynolds PET imaging of serotonin type 2A receptors in late-life neuropsychiatric disorders Am. J. Psychiatry 156 1999 1871 1878
33. J.H. Meyer Applying neuroimaging ligands to study major depressive disorder Semin. Nucl. Med. 38 2008 287 304
34. 18F]setoperone PET imaging study Am. J. Psychiatry 156 1999 1029 1034
35. J.H. Meyer, S. Kapur, B. Eisfeld, G.M. Brown, S. Houle, J. DaSilva, A.A. Wilson, S. Rafi-Tari, H.S. Mayberg, and S.H. Kennedy The effect of paroxetine on 5-HT(2A) receptors in depression: an [(18)F]setoperone PET imaging study Am. J. Psychiatry 158 2001 78 85
36. 18F]altanserin positron emission tomography Biol. Psychiatry 55 2004 217 224
37. 2A-mGlu2) receptor heteromerization and its psychoactive behavioral function J. Biol. Chem. 287 2012 44301 44319
38. 2A receptor binding in postmortem frontal cortex of schizophrenic subjects Eur. Neuropsychopharmacol. 23 2013 852 864
39. 2A receptor binding correlates with lifetime aggression in suicide Biol. Psychiatry 59 2006 235 243
40. F. Owen, A.J. Cross, T.J. Crow, J.F. Deakin, I.N. Ferrier, R. Lofthouse, and M. Poulter Brain 5-HT-2 receptors and suicide Lancet 2 1983 1256
41. A. Palucha, P. Branski, K. Klak, and M. Sowa Chronic imipramine treatment reduces inhibitory properties of group II mGlu receptors without affecting their density or affinity Pharmacol. Rep. 59 2007 525 530
42. 2A receptors in the postmortem brains of teenage suicide victims Am. J. Psychiatry 159 2002 419 429
43. G. Rajkowska, and P.S. Goldman-Rakic Cytoarchitectonic definition of prefrontal areas in the normal human cortex: I. Remapping of areas 9 and 46 using quantitative criteria Cereb. Cortex 5 1995 307 322
44. 3) levels in hippocampus but not in frontal cortex from depressed suicide victims Psychiatry Res. 99 2000 173 181
45. 3 and cAMP in brains from depressed violent suicide victims Neuropsychobiology 49 2004 189 195
46. G. Sanacora, G. Treccani, and M. Popoli Towards a glutamate hypothesis of depression: an emerging frontier of neuropsychopharmacology for mood disorders Neuropsychopharmacology 62 2012 63 77
47. M.C. Sampedro, N. Unceta, A. Gomez-Caballero, L.F. Callado, B. Morentin, M.A. Goicolea, J.J. Meana, and R.J. Barrio Screening and quantification of antipsychotic drugs in human brain tissue by liquid chromatography-tandem mass spectrometry: application to postmortem diagnostics of forensic interest Forensic Sci. Int. 219 2012 172 178
48. A. Sequeira, F. Mamdani, C. Ernst, M.P. Vawter, W.E. Bunney, V. Lebel, S. Rehal, T. Klempan, A. Gratton, C. Benkelfat, G.A. Rouleau, N. Mechawar, and G. Turecki Global brain gene expression analysis links glutamatergic and GABAergic alterations to suicide and major depression PLoS One 4 2009 e6585
49. T. Sharp, and P.J. Cowen 5-HT and depression: is the glass half-full? Curr. Opin. Pharmacol. 11 2011 45 51
50. Y.I. Sheline, M.A. Mintun, D.M. Barch, C. Wilkins, A.Z. Snyder, and S.M. Moerlein Decreased hippocampal 5-HT(2A) receptor binding in older depressed patients using [18F]altanserin positron emission tomography Neuropsychopharmacology 29 2004 2235 2241
51. E. Sibille, V. Arango, H.C. Galfalvy, P. Pavlidis, L. Erraji-Benchekroun, S.P. Ellis, and J. Mann Gene expression profiling of depression and suicide in human prefrontal cortex Neuropsychopharmacology 29 2004 351 361
52. C.A. Stockmeier, G.E. Dilley, L.A. Shapiro, J.C. Overholser, P.A. Thompson, and H.Y. Meltzer Serotonin receptors in suicide victims with major depression Neuropsychopharmacology 16 1997 162 173
53. G. Turecki, R. Briere, K. Dewar, T. Antonetti, A.D. Lesage, M. Seguin, N. Chawky, C. Vanier, M. Alda, R. Joober, C. Benkelfat, and G.A. Rouleau Prediction of level of serotonin 2A receptor binding by serotonin receptor 2A genetic variation in postmortem brain samples from subjects who did or did not commit suicide Am. J. Psychiatry 156 1999 1456 1458
54. M.D. Underwood, S.A. Kassir, M.J. Bakalian, H. Galfalvy, J.J. Mann, and V. Arango Neuron density and serotonin receptor binding in prefrontal cortex in suicide Int. J. Neuropsychopharmacol. 15 2012 435 447
55. C.H. West, J.C. Ritchie, K.A. Boss-Williams, and J.M. Weiss Antidepressant drugs with differing pharmacological actions decrease activity of locus coeruleus neurons Int. J. Neuropsychopharmacol. 12 2009 627 641
56. H.A. Whiteford, L. Degenhardt, J. Rehm, A.J. Baxter, A.J. Ferrari, H.E. Erskine, F.J. Charlson, R.E. Norman, A.D. Flaxman, N. Johns, R. Burstein, C.J. Murray, and T. Vos Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010 Lancet 382 2013 1575 1586
57. J.M. Wierońska, B. Legutko, D. Dudys, and A. Pilc Olfactory bulbectomy and amitriptyline treatment influences mGlu receptors expression in the mouse brain hippocampus Pharmacol. Rep. 60 2008 844 855
58. L.N. Yatham, P.F. Liddle, J. Dennie, I.S. Shiah, M.J. Adam, C.J. Lane, R.W. Lam, and T.J. Ruth Decrease in brain serotonin 2 receptor binding in patients with major depression following desipramine treatment: a positron emission tomography study with fluorine-18-labeled setoperone Arch. Gen. Psychiatry 56 1999 705 711
59. L.N. Yatham, P.F. Liddle, I.S. Shiah, G. Scarrow, R.W. Lam, M.J. Adam, A.P. Zis, and T.J. Ruth Brain serotonin2 receptors in major depression: a positron emission tomography study Arch. Gen. Psychiatry 57 2000 850 858